Utility of homology models in the drug discovery process

Drug Discovery Today

Volumn 9, Issue 15, 2004, Pages 659-669

  Hillisch, Alexander ^a   Pineda, Luis Felipe ^a   Hilgenfeld, Rolf ^b  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

assessment of target druggability; Chemical Biology; Drug Discovery; Homology modeling; Pharmaceutical Science; prediction of animal model suitability; prediction of drug metabolism; structural bioinformatics; Structural Biology; structure based drug design

Indexed keywords

ANTIVIRUS AGENT; AZACITIDINE; CYTOCHROME P450; ESTRADIOL; GLUCOCORTICOID; MIFEPRISTONE; POTASSIUM CHANNEL HERG; RECEPTOR BLOCKING AGENT; RETINOIC ACID RECEPTOR ALPHA ANTAGONIST; RUPINTRIVIR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

BIOINFORMATICS; COMMON COLD; CONFORMATION; CRYSTAL STRUCTURE; DATA BASE; DNA METHYLATION; DRUG INDUSTRY; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INDUCTION; GENE SEQUENCE; HUMAN; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN STRUCTURE; QT PROLONGATION; REVIEW; SARS CORONAVIRUS; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; MODELS, MOLECULAR; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 3242813635     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03196-4     Document Type: Review

References (84)

1. Giersiefen H., et al. Modern Methods of Drug Discovery: An Introduction. Hillisch A., Hilgenfeld R. Modern Methods of Drug Discovery. 2003;1-18 Birkhäuser Verlag
2. Lesk A.M., Chothia C. The response of protein structures to amino-acid sequence changes. Philos. Trans. R. Soc. Lond. B Biol. Sci. 317:1986;345-356
3. Godzik A. Fold Recognition Methods. Bourne P., Weissig H. Structural Bioinformatics. 2003;525-546 Wiley-Liss
4. Murzin A.G. Progress in protein structure prediction. Nat. Struct. Biol. 8:2001;110-112
5. Tramontano A., et al. Assessment of homology-based predictions in CASP5. Proteins. 53:2003;352-368
6. Murzin A.G., et al. SCOP: a structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol. 247:1995;536-540
7. Hendlich M. Databases for protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 54:1998;1178-1182
8. Stuart A.C., et al. LigBase: a database of families of aligned ligand binding sites in known protein sequences and structures. Bioinformatics. 18:2002;200-201
9. Laskowski R.A. PDBsum: summaries and analyses of PDB structures. Nucleic Acids Res. 29:2001;221-222
10. Pieper U., et al. MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res. 32:2004;D217-D222
11. Sali A., et al. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:1993;779-815
12. Kopp J., et al. The SWISS-MODEL Repository of annotated three-dimensional protein structure homology models. Nucleic Acids Res. 32:2004;D230-D234
13. Debe D.A., Hambly K. Supporting your pipeline with structural knowledge. Curr. Drug Discov. 3:2004;15-18
14. Chothia C., et al. The relation between the divergence of sequence and structure in proteins. EMBO J. 5:1986;823-826
15. Kinch L.N., et al. CASP5 assessment of fold recognition target predictions. Proteins. 53:2003;395-409
16. Hillisch A., Hilgenfeld R. The role of protein 3D structures in the drug discovery process. Hillisch A., Hilgenfeld R. Modern Methods of Drug Discovery. 2003;157-181 Birkhäuser Verlag
17. Hardy L.W., et al. The impact of structure-guided drug design on clinical agents. Curr. Drug Discov. 12:2003;15-20
18. Hopkins A.L., et al. The druggable genome. Nat. Rev. Drug Discov. 1:2002;727-730
19. Walters W.P., et al. Prediction of 'drug-likeness'. Adv. Drug Deliv. Rev. 54:2002;255-271
20. Sadowski J., et al. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 41:1998;3325-3329
21. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44:2000;235-249
22. Fauman E.B., et al. Structural bioinformatics in drug discovery. Methods Biochem. Anal. 44:2003;477-497
23. Chene P. Inhibition of the p53-hdm2 interaction with low molecular weight compounds. Cell Cycle. 3:2004;460-461
24. Chene P. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. Mol. Cancer Res. 2:2004;20-28
25. Schmitt S., et al. A new method to detect related function among proteins independent of sequence and fold homology. J. Mol. Biol. 323:2002;387-406
26. Binkowski T.A., et al. Inferring functional relationships of proteins from local sequence and spatial surface patterns. J. Mol. Biol. 332:2003;505-526
27. Naumann T., et al. Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. J. Med. Chem. 45:2002;2366-2378
28. Steinmetzer K., et al. Transcriptional repressor CopR: structure model-based localization of the deoxyribonucleic acid binding motif. Proteins. 38:2000;393-406
29. Eyers P.A., et al. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett. 451:1999;191-196
30. Bredel M., et al. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet. 5:2004;262-275
31. Hillisch A., et al. Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol. Endocrinol. 18:2004;1599-1609
32. Hegele-Hartung C., et al. Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc. Natl. Acad. Sci. U. S. A. 101:2004;5129-5134
33. Pike A.C., et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18:1999;4608-4618
34. Manning G., et al. The protein kinase complement of the human genome. Science. 298:2002;1912-1934
35. Traxler P., et al. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. J. Pharm. Belg. 52:1997;88-96
36. Ghosh S., et al. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. Curr. Cancer Drug Targets. 1:2001;129-140
37. Mahajan S., et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13. J. Biol. Chem. 274:1999;9587-9599
38. Sudbeck E.A., et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 5:1999;1569-1582
39. Vankayalapati H., et al. Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol. Cancer Ther. 2:2003;283-294
40. Honma T., et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. 44:2001;4615-4627
41. Vangrevelinghe E., et al. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 46:2003;2656-2662
42. Siedlecki P., et al. Establishment and functional validation of a structural homology model for human DNA methyltransferase 1. Biochem. Biophys. Res. Commun. 306:2003;558-563
43. Barrow J.C., et al. Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J. Med. Chem. 46:2003;5294-5297
44. + channels. J. Biol. Chem. 275:2000;1201-1208
45. Anand K., et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 21:2002;3213-3224
46. Anand K., et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 300:2003;1763-1767
47. Rota P.A., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 300:2003;1394-1399
48. Matthews D.A., et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A. 96:1999;11000-11007
49. Yang H., et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U. S. A. 100:2003;13190-13195
50. Takeda-Shitaka M., et al. Evaluation of homology modeling of the severe acute respiratory syndrome (SARS) coronavirus main protease for structure-based drug design. Chem. Pharm. Bull. (Tokyo). 52:2004;643-645
51. Xiong B., et al. A 3D model of SARS CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharmacol. Sin. 24:2003;497-504
52. Palczewski K., et al. Crystal structure of rhodopsin: A G-protein-coupled receptor. Science. 289:2000;739-745
53. Becker O.M., et al. Modeling the 3D structure of GPCRs: advances and application to drug discovery. Curr. Opin. Drug Discov. Devel. 6:2003;353-361
54. Schapira M., et al. Nuclear hormone receptor targeted virtual screening. J. Med. Chem. 46:2003;3045-3059
55. Schapira M., et al. Rational discovery of novel nuclear hormone receptor antagonists. Proc. Natl. Acad. Sci. U. S. A. 97:2000;1008-1013
56. Bissantz C., et al. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein-coupled receptors suitable targets? Proteins. 50:2003;5-25
57. Schafferhans A., et al. Docking ligands onto binding site representations derived from proteins built by homology modelling. J. Mol. Biol. 307:2001;407-427
58. Oshiro C., et al. Performance of 3D database molecular docking studies into homology models. J. Med. Chem. 47:2004;764-767
59. Steinrücke P., et al. Design of helical proteins for real-time endoprotease assays. Anal. Biochem. 286:2000;26-34
60. Benhamou B., et al. A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science. 255:1992;206-209
61. Gray G.O., et al. RU486 is not an antiprogestin in the hamster. J. Steroid Biochem. 28:1987;493-497
62. Williams P.A., et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell. 5:2000;121-131
63. Schoch G.A., et al. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J. Biol. Chem. 279:2004;9497-9503
64. Williams P.A., et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 424:2003;464-468
65. Lewis D.F. Molecular modeling of human cytochrome P450-substrate interactions. Drug Metab. Rev. 34:2002;55-67
66. Lewis D.F. Modelling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template. J. Inorg. Biochem. 91:2002;502-514
67. Lewis D.F., et al. Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica. 33:2003;239-254
68. Lewis D.F., et al. Homology modelling of CYP2A6 based on the CYP2C5 crystallographic template: enzyme-substrate interactions and QSARs for binding affinity and inhibition. Toxicol. In Vitro. 17:2003;179-190
69. Lewis D.F., et al. Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: analysis of enzyme-substrate interactions. Drug Metabol. Drug Interact. 19:2002;115-135
70. Lewis D.F., et al. A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions. Drug Metabol. Drug Interact. 19:2003;189-210
71. Lewis D.F., et al. Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic template. Drug Metabol. Drug Interact. 19:2003;257-285
72. Vermeulen N.P. Prediction of drug metabolism: the case of cytochrome P450 2D6. Curr. Top. Med. Chem. 3:2003;1227-1239
73. De Groot M.J., et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 42:1999;4062-4070
74. Afzelius L., et al. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol. Pharmacol. 59:2001;909-919
75. Szklarz G.D., et al. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab. Dispos. 26:1998;1179-1184
76. Mankowskia D.C., et al. Prediction of human drug metabolizing enzyme induction. Curr. Drug Metab. 4:2003;381-391
77. Watkins R.E., et al. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J. Mol. Biol. 331:2003;815-828
78. Dussault I., et al. A structural model of the constitutive androstane receptor defines novel interactions that mediate ligand-independent activity. Mol. Cell. Biol. 22:2002;5270-5280
79. Xiao L., et al. Insights from a three-dimensional model into ligand binding to constitutive active receptor. Drug Metab. Dispos. 30:2002;951-956
80. Lewis D.F., et al. Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor alpha (hERalpha) LBD: quantitative structure-activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement. J. Steroid Biochem. Mol. Biol. 82:2002;195-199
81. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov. Today. 9:2004;276-285
82. Mitcheson J.S., et al. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12329-12333
83. Pearlstein R.A., et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 13:2003;1829-1835
84. Hillisch A., Hilgenfeld R. Modern Methods of Drug Discovery. 2003;Birkhäuser Verlag AG